



ORIGINAL ARTICLE

Clinical Response to Different Medical Treatment Options for Mastalgia in Fibrocystic Breast Disease among Women at a Tertiary Care Hospital in Dhaka City

Samia Mostary¹, Md. Manir Hossain Khan², Md. A. Mottalab Hossain³, Tapash Kumar Maitra⁴

¹MS [General Surgery], Resident of Surgery, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka, Bangladesh; ²Associate Professor, Department of Surgery, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; ³Professor, Department of Surgery, Sir Salimullah Medical College and Mitford Hospital, Dhaka, Bangladesh; ⁴Professor & Head, Department of General Surgery, Ibrahim Medical College, Dhaka, Bangladesh

[Received on: 1 February 2021; Accepted on: 20 March 2021; Published on: 1 July 2021]

Abstract

Background: Various types of medical management are given for mastalgia in fibrocystic breast disease. **Objective:** The aim of this study was to compare the effects of different commonly used medical management options of mastalgia of fibrocystic breast disease on the quality of life of the respondents and their side effects as well. **Methods:** This prospective longitudinal study was carried out in Out-patients Department of General Surgery, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM) General Hospital, Dhaka, Bangladesh from July 2018 to June 2019. The patients with fibrocystic breast disease were selected according to the eligibility criteria and are allocated to two groups by alternative random selection. In non-pharmacological treatments receiving group, lifestyle modification advices along with Evening Primrose Oil were given. On the other hand, in pharmacological treatment receiving group, Bromocriptine and Danazole were given according to some selection criteria of the patients. Response of treatments to each group & side effects were determined at one month, three months and six months follow up respectively. **Results:** A total number of 45 patients were recruited for this study. Majority of them presented with cyclical mastalgia (57.78%), bilateral mastalgia (60%) and mastalgia with lumpiness (44.4%). Among the patients who received non-pharmacological treatment, mastalgia improved in 34.78% cases and patients received pharmacological treatment, mastalgia improved in 72.73% cases. Different domains of quality of life were improved significantly in patients who received pharmacological treatment. **Conclusion:** In conclusion pharmacological management by Danazol or Bromocriptine has well tolerated to the patients. [Journal of Current and Advance Medical Research, July 2021;8(2):95-99]

Keywords: Fibrocystic breast disease; mastalgia; EPO; danazol; bromocriptin; quality of life

Correspondence: Dr. Samia Mostary, Department of General Surgery, BIRDEM General Hospital, Shahbag, Dhaka, Bangladesh; **Email:** dr.samiamostary@gmail.com; Cell No.: +8801739492880

Cite this article as: Mostary S, Khan MMH, Hossain MAM, Maitra TK. Clinical Response to Different Medical Treatment Options for Mastalgia in Fibrocystic Breast Disease among Women at a Tertiary Care Hospital in Dhaka City. J Curr Adv Med Res 2021;8(2):95-99

Funding: This study has been performed without any funding from outside else.

Conflict of Interest: There was no conflict of interest to any of the authors.

Contributions to authors: Mostary S, Khan MMH were involved in study designing, data collection, compiling, data analysis. BD wrote the manuscript. Rests were involved in overall supervision.

Copyright: ©2021. Mostary et al. Published by Journal of Current and Advance Medical Research. This article is published under the Creative Commons CC BY-NC License (<https://creativecommons.org/licenses/by-nc/4.0/>). This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and is not used for commercial purposes.

Introduction

Fibrocystic breast disease (FBD) is the most common type of benign breast disease¹ and mastalgia is the most common symptom of FBD². It represents a spectrum of clinical, radiological and histological findings of the breast in both asymptomatic and symptomatic women. Mastalgia causes concern and fear of breast cancer and has negative effects on quality of life³. Mastalgia caused by fibrocystic breast disease is treated by breast specialists as well as by those not specialized in breast diseases⁴. Unfortunately, these patients are treated inappropriately for prolonged duration with non-pharmacological management by Evening Primrose Oil^{2,5} in a fear of more side effects of pharmacological managements by certain drugs⁶.

Inappropriate selection of non-pharmacological treatment as a first line management option, sometimes creates financial burden and unchanged or recurrence of clinical symptoms⁷. Recent population based and breast clinic-based studies suggest that up to 70% of women experience breast pain in their lifetime⁸. Moreover, 10% of symptomatic participants had suffered breast pain for over half their lives. Of the symptomatic participants, 41% and 35% reported breast pain affecting the quality of life⁹. Fifteen percent of women who present to a breast clinic with mastalgia will require treatment^{8,9}.

Non pharmacological options of medical managements includes some life style modifications (LSM) like- an appropriately fitting and supportive bra, avoidance of caffeine drinks, reduction of dietary fat, increase fiber rich diet, physical exercise to reduce weight and relaxation training are said to be helpful for the treatment of mastalgia¹⁰ and some nutritional supplementations like oil of evening primrose (EPO) will help more than half of these women^{5,10,11}. For those with intractable symptoms, Pharmacological options of medical management like- an anti-gonadotropin, Danazol⁶, or a prolactin inhibitor like bromocriptine⁵, may be tried. Very rarely, it is necessary to prescribe an anti-estrogen, for example tamoxifen^{12,13}, or a luteinizing hormone-releasing hormone (LHRH) agonist to deprive the breast epithelium of estrogenic drive. Surgical interventions have a limited role in the management of mastalgia⁵ but last-resort options for unresponsive and severe debilitating breast-pain include mastectomy with reconstruction¹⁴. The aim of this present study was to assess the responses of various medical treatment options of mastalgia of

FBD on women's quality of life as well as side effects of used medications.

Methodology

It was a Prospective longitudinal study carried out in Outpatient department (OPD) of General Surgery, BIRDEM General Hospital, Dhaka, from July 2018 to June 2019. The patients with fibrocystic breast disease (FBD) presented in OPD of BIRDEM General Hospital, Dhaka, Bangladesh were selected as study population. The inclusion criteria were women of reproductive age group and patients diagnosed as fibrocystic breast disease by clinical, radiological or cytological examinations within the study period. Patients with suspected breast lesion or diagnosed breast malignancy, pregnant, lactating women and who were planning to have pregnancy in near future, history of any breast surgery or having congenital disability of breast were excluded from this study. A thorough history of each patient was obtained and careful physical examination carried out of each patient. Hormonal assay and USG of both breasts were done in every patient but Mammography and FNAC were done only in suspected cases to exclude FBD and occult breast carcinomas, particularly in patient having family history of breast diseases. Patients were allocated to two groups by alternative random selection (first one to non-pharmacological and second one to pharmacological, third to again non-pharmacological treatment receiving group and so on. Non-pharmacological treatments receiving group were given life style modification (LSM) advices along with Evening Primrose Oil (EPO). The LSM advices were wearing a supportive bra, exercise to reduce weight, reduction of mental stress by relaxation therapy, some dietary advices such as reduction of fat and caffeine intake, increase dietary fiber intake, etc. Evening Primrose Oil (EPO) was given orally in a dose of 1000mg thrice daily. In pharmacological treatment receiving group Bromocriptine and Danazole were given according to some selection criteria of the patients. Bromocriptine was given orally in a dose of 2.5mg twice daily, in those patient with increased prolactin level, having no known hypersensitivity to it, not taking any anticonvulsant, not having uncontrolled diabetes, severe ischemic heart disease or migraine. On the other hand, Danazole was given orally in a dose of 100mg twice daily in patients with normal prolactin level, hyperestrogenaemia, patients with no undiagnosed genital bleeding, previous thromboembolic disorders or markedly impaired hepatic, renal or cardiac functions. In both groups oral analgesics were given according to the severity of mastalgia. Acetaminophen was given 500mg

thrice daily for VAS 2-4 and Ibuprofen was given 200mg twice daily for VAS ≥ 6 in initial visit for one week to alleviate the severity of pain in both groups. Patients were advised not to take any analgesic after initial one week and report if the pain became intolerable. Response to each group of treatments, side effects & compliance of the patient were determined at 1 month, 3 months and 6 months follow up respectively. Mastalgia was measured by VAS score and QOL were calculated by modified WHO-QOL scoring (field trial version) in each follow up. Any side effects, willingness to continue the treatment were also asked to every patient in each follow up. No treatment was changed before 3 months of therapy, no matter what the response was. This study focused simply on the comparison of the two groups of medical treatments of mastalgia and their responses of QOL at beginning and after 6 months of treatment. Ethical clearance for this thesis work was taken from the Institutional Review Board (IRB) of BIRDEM General Hospital (No. BIRDEM /IRB/2017 /78) on 21 June, 2017. Informed Written Consents were taken from every patient.

Results

This was a Prospective type of longitudinal study conducted in OPD of BIRDEM General Hospital, Dhaka, Bangladesh. Total number of respondents

were 45. Highest respondents of our study were aged between 31 to 35 years (33.3%) and no respondents were aged between 45 to 50 years (0%). Mean age of the respondents were 30.24±6.93 years of SD (Table 1).

Table 1: Age Distribution among Respondents (n= 45)

Age Group	Frequency	Percent
16 to 20 years	4	8.9
21 to 25 years	10	22.2
26 to 30 years	11	24.4
31 to 35 years	15	33.3
36 to 40 years	3	6.7
41 to 45 years	2	4.4
46 to 50 years	0	0.0
Total	45	100.0

In pharmacological treatment received group 40.91% respondents treated with Danazole and 59.09% treated with Bromocriptine. After 6 months follow up, 72.73% had pain improvement in pharmacologically treated group and 34.78% had pain improvement in non-pharmacological group. Significant difference had been found between both groups. Here VAS 0-2 was considered as pain improvement and VAS 4 and above was considered as non-improvement of pain (Table 2).

Table 2: Distribution of the Respondents by 6 months follow up of non-pharmacological and Pharmacological Treatment using QOL parameters

Facets Incorporated Within Domains	Non pharmacological (n=23)		Pharmacological (n=22)		P value
	Improved	Not Improved	Improved	Not Improved	
Domains of QOL					
• Pain	8(34.8%)	15(65.2%)	16(72.7%)	6(27.3%)	*0.006
• Physical health	9(39.1%)	14(60.9%)	16(72.7%)	6(27.3%)	*0.008
Physical domain					
• Energy & Fatigue	8(34.8%)	15(65.2%)	15(68.2%)	7(31.8%)	*0.001
• Sleep & Rest	10(43.5%)	13(56.5%)	17(77.3%)	5(22.7%)	*0.05
• Self esteem	7(30.4%)	16(69.6%)	14(63.6%)	8(36.4%)	*0.031
Psychological domain					
• Concentration/ Attention	9(39.1%)	14(60.9%)	13(59.1%)	9(40.9%)	*0.002
• Negative feeling	6(26.1%)	17(73.9%)	12(54.5%)	10(45.5%)	*0.003
Social Relationship					
• Personal relationship	8(34.8%)	15(65.2%)	12(54.5%)	10(45.5%)	*0.151
• Sexual life	7(30.4%)	16(69.6%)	13(59.1%)	9(40.9%)	*0.08

*P value was determined by Chi-square test; Negative feeling=Anxiety, Depression

Table 3: Distribution of side effects of different Pharmacological and non-pharmacological treatment options

Adverse Effect	Frequency	Percent
Danazole		
Weight gain	6	13.3
Menstrual irregularity	7	15.6
Headache	5	11.1
Nausea	2	4.4
Acne	1	2.2
Non specific	4	8.9
Bromocriptine		
Headache	5	11.1
Nausea	2	4.4
Dyspepsia	2	4.4
Non specific	3	6.7
Evening Primrose Oil (EPO)		
Bloating	3	6.7
Headache	1	(.2

Discussion

Mastalgia with or without breast lump in FBD is common complaint among the patients and a cause of significant anxiety and fear of female breast cancer in Bangladesh as well as all over the world. In this study maximum respondents were age between 31 to 35 years (33.3%). The mean age of the respondents were 30.24±6.93 years of SD. Similar observations were found in some previous studies by Scurr et al⁹ and in a recent study done by Godazandeh et al¹⁵.

In this study 51.1% respondents underwent non-pharmacological treatment by LSM and EPO and 48.9% underwent pharmacological treatment, where 40.91% respondents treated with Danazole and 59.09% treated with Bromocriptine depending on the selection criteria.

In this study quality of life (QOL) in non-pharmacological treatment receiving group- in physical domain: pain 34.78%, physical health 39.13%, energy and fatigue 34.78% and sleep and rest 43.48% had improvement. In psychological domain: 30.43% had improvement of self-esteem, 39.13 % had improvement in concentration/attention and 26.09 % had improvement in negative feeling. In social relationship domain: in personal relationship 34.78% and in sexual life 30.63% had improvement. Beside in pharmacological treatment receiving group in physical domain: pain 72.73%, physical health 72.72%, energy and fatigue 68.18% and sleep and rest 77.27% had improvement. In

psychological domain: in self-esteem 63.64%, concentration/attention 59.09% and 54.55% negative feeling had improvement. In social domain: 54.55% personal relationship and 59.09% sexual life had improvement. In all domains improvements were significantly higher in pharmacological group.

Similar observation was seen in a previous study by Rajswaroob et al¹⁷ where he showed drug treatment was significantly effective for mastalgia. Ganz et al²⁰ observed mood and emotional functioning were same among all patients, with no differences by type of medical treatment received which is abit differ from our observation.

In this study majority of side effects occurred due to Danazole. Chronologically they are menstrual irregularity (15.6%), weight gain (13.3%), headache (11.1%), nausea (4.4%), acne (2.2%) and nonspecific side effects (8.9%). Beside headache (11.1%), nausea (4.4%), dyspepsia (4.4%) and nonspecific side effects (6.7%) due to Bromocriptine. Whereas only 6.7% had bloating and 2.2% had headache due to Evening Primrose oil (EPO). Here a single patient sometimes complained of multiple side effects. Almost similar observation was seen in some previous study by Rajswaroob et al¹⁷ and Neogi et al²¹ and Nirhale et al⁸.

There are some limitations of this study. This study was performed in a single tertiary care hospital among small available population size.

Conclusion

In this study, It has been found pharmacological managements by Danazole or Bromocriptine in precisely selected group of patients were well tolerated and a dramatic improvement was observed in overall quality of life of our patients. Despite of having various side effects of different pharmacological managements of mastalgia, it has been recommended timely use of them in the precisely selected patients of fibrocystic breast disease can help in reduction of their sufferings, cost of prolonged treatments by improving the quality of life in a relatively shorter period of time. Further large study is recommended involving multiple centers and long term follow up.

References

1. Ameen F, Reda SA, El-Shatoury SA, Riad EM, Enany ME, Alarfaj AA. Prevalence of antibiotic resistant mastitis pathogens in dairy cows in Egypt and potential biological control agents produced from plant endophytic actinobacteria. *Saudi journal of biological sciences*. 2019 Nov 1;26(7):1492-8.
2. Jahdi F, Tolouei R, Neisani Samani L, Hashemian M, Haghani H, Mojab F, Memarzadeh M. Effect of evening primrose oil and vitamin b6 on pain control of cyclic mastalgia associated with fibrocystic breast changes: a triple-blind randomized controlled trial. *Shiraz E-Medical Journal*. 2019 May 31;20(5).
3. Kanat BH, Atmaca M, Girgin M, Ilhan YS, Bozdağ A, Özkan Z, Yazar FM, Emir S. Effects of mastalgia in young women on quality of life, depression, and anxiety levels. *Indian Journal of Surgery*. 2016 Apr;78(2):96-9.
4. Marchant DJ. Inflammation of the breast. *Obstetrics and Gynecology Clinics*. 2002 Mar 1;29(1):89-102.
5. Salati SA, Alhumaid AA. Mastalgia: A narrative literature review of current understanding and management. *East and Central African Journal of Surgery*. 2018 Jul 16;23(1):42-51.
6. Cornell LF, Sandhu NP, Pruthi S, Mussallem DM. Current Management and Treatment Options for Breast Pain. *In Mayo Clinic Proceedings* 2020; 95(3):574-580
7. Nicola LP,B,Shazia P.H.,Cilona C,Kirwan. Clinical management of idiopathic mastalgia: a systemic review. *J Prime Health Care*, 2018; 10(4): 312-323.
8. Nirhale DS, Dhende M, Shingade P, Chavan S, Sonawane T, Kulkarni G. A study on clinical profile and management of mastalgia. *International Surgery Journal*. 2018 Apr 21;5(5):1889-93
9. Scurr J, Hedger W, Morris P, Brown N. The prevalence, severity, and impact of breast pain in the general population. *The Breast Journal*. 2014 Sep; 20(5):508-13
10. Murshid, KR 2011, 'A review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options', *Journal of Taibah University Medical Sciences*, vol. 6, no. 1, pp. 1-18.
11. Pruthi, S, Wahner-Roedler, DL, Torkelson, CJ, Cha, SS, Thicke, LS, Hazelton, JH & Bauer, BA, 2010, 'Vitamin E and evening primrose oil for management of cyclical mastalgia: A randomized pilot study', *Alternative Medicine Review*, vol. 15, no. 1, pp. 59-67.
12. Ortiz-Mendoza CM, Lucas Flores MA, Domville Ede G. Mastalgia treatment with tamoxifen'. [Article in Spanish]. *Ginecol Obstet Mex*. 2003;71:502-7.
13. Jain BK, Bansal A, Choudhary D, Garg PK, Mohanty D. Centchroman vs tamoxifen for regression of mastalgia: a randomized controlled trial. *International Journal of Surgery*. 2015 Mar 1; 15:11-6.
14. Groen JW, Grosfeld S, Bramer WM, Ernst MF, Mullender MM. Cyclic and non-cyclic breast-pain: A systematic review on pain reduction, side effects, and quality of life for various treatments. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2017 Dec 1; 219:74-93.
15. Godazandeh G, Ala S, Motlaq TM, Sahebhasagh A, Bazi A. The comparison of the effect of flaxseed oil and vitamin E on mastalgia and nodularity of breast fibrocystic: a randomized double-blind clinical trial. *Journal of Pharmaceutical Health Care and Sciences*. 2021 Dec;7(1):1-8.
16. Çomçalı B, Kocaoz S, Özdemir BA, Parlak Ö, Korukluoğlu B. Effects of sagging breasts and other risk factors associated with mastalgia: a case-control study. *Scientific Reports*. 2021 Jan 29;11(1):1-7.
17. Rajswaroob U, Kannan R, Kannan NS, Tirouaroul T. Effectiveness of centchroman on regression of fibroadenosis and mastalgia. *Journal of clinical and diagnostic research: JCDR*. 2016 Oct;10(10):PC10-14.
18. Sangma MB, Panda K, Dasiah S. A clinico-pathological study on benign breast diseases. *Journal of clinical and diagnostic research: JCDR*. 2013 Mar;7(3):503-06.
19. Smith RL, Pruthi S, Fitzpatrick LA. Evaluation and management of breast pain. *In Mayo Clinic Proceedings* 2004;79(3):353-372
20. Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, et al 2004, 'Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial', vol. 96, no. 5.
21. Neogi P, Manwatkar S, Singh SK, Kola A, Imran Q, Katyayan I, Verma A. A comparative study of Centchroman, Tamoxifen and Danazol in management of cyclical mastalgia. *International Surgery Journal*. 2019 Jan 28;6(2):365-8.